View Older Stories

Jan 12, 2026 09:10AM Lexaria Bioscience CEO outlines 2025 progress and 2026 plans

Jan 12, 2026 09:10AM Lexaria Releases Annual Letter from the CEO

Dec 30, 2025 09:20AM Lexaria reports additional Phase 1b study results for drug delivery platform

Dec 30, 2025 09:20AM Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Dec 29, 2025 05:13PM Lexaria Bioscience (LEXX) files for 2.75M share offering by selling stockholders

Dec 26, 2025 06:42AM Lexaria Bioscience (LEXX) PT Lowered to $1.50 at H.C. Wainwright

Dec 23, 2025 09:29AM Lexaria achieves primary endpoint in Phase 1b GLP-1 study

Dec 23, 2025 09:29AM Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Dec 16, 2025 04:00PM Lexaria Bioscience closes $3.5 million registered direct offering

Dec 16, 2025 04:00PM Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025 08:01AM Lexaria Bioscience raises $3.5 million in registered direct offering

Dec 15, 2025 08:00AM Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 5, 2025 04:03PM Lexaria Bioscience (LEXX) files for 2.76M share offering by selling stockholders

Nov 12, 2025 09:11AM Lexaria extends pharmaceutical partnership agreement through April 2026

Nov 12, 2025 09:10AM Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Oct 9, 2025 09:20AM Lexaria Bioscience hires advisory firm, receives 4 new patents

Oct 9, 2025 09:20AM Lexaria Bioscience Corp. Provides Strategic Update

Sep 29, 2025 04:30PM Lexaria Bioscience closes $4 million registered direct offering

Sep 29, 2025 04:30PM Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025 08:00AM Lexaria Bioscience raises $4 million in registered direct offering

Sep 26, 2025 08:00AM Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 19, 2025 11:25AM Lexaria reports enhanced brain delivery of semaglutide using DehydraTECH

Sep 19, 2025 11:20AM Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Aug 27, 2025 09:20AM Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Aug 14, 2025 09:20AM Lexaria completes patient dosing in Phase 1b GLP-1 study

Aug 14, 2025 09:20AM Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 6, 2025 09:20AM GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Jul 29, 2025 06:41AM Lexaria Bioscience (LEXX) PT Lowered to $4 at H.C. Wainwright

Jul 28, 2025 09:25AM Lexaria reports reduced side effects in GLP-1 drug trial

Jul 28, 2025 09:25AM Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Jul 23, 2025 09:28AM Lexaria claims technology could reduce GLP-1 drug side effects

Jul 23, 2025 09:25AM Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Jul 1, 2025 06:42AM Lexaria Bioscience (LEXX) PT Lowered to $5 at H.C. Wainwright

Jun 23, 2025 09:15AM Lexaria Bioscience (LEXX) Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Jun 23, 2025 09:15AM Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Jun 13, 2025 04:10PM Lexaria Bioscience (LEXX) Files for 41.63M Share Offering by Selling Stockholders

Jun 11, 2025 09:05AM Lexaria's (LEXX) DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Jun 11, 2025 09:05AM Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Jun 5, 2025 09:20AM Lexaria Attending BIO International Convention

May 12, 2025 09:02AM Lexaria Bioscience (LEXX) Provides Update on Material Transfer Agreement with Pharmaceutical Company

May 12, 2025 09:00AM Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Apr 28, 2025 04:15PM Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025 08:02AM Lexaria Bioscience (LEXX) Prices 2M Share Offering at $1/sh

Apr 25, 2025 08:00AM Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Apr 23, 2025 09:10AM Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

Apr 3, 2025 09:14AM Lexaria Bioscience (LEXX) Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025 09:10AM Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 2, 2025 09:13AM Lexaria Bioscience (LEXX) announces human dosing in GLP-1 study

Apr 2, 2025 09:05AM Lexaria's Human GLP-1 Study #5 Begins Dosing

Mar 18, 2025 09:16AM Lexaria Bioscience's (LEXX) DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound

View Older Stories